OncoMatch/Clinical Trials/NCT07239245
Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo
Is NCT07239245 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Atezolizumab and Bevacizumab for resectable hepatocellular carcinoma with high risk of recurrence.
Treatment: Atezolizumab · Bevacizumab — This is an open-label, single-arm, multicenter, prospective, phase II clinical study to evaluate the efficacy and safety of TACE combined with Atezolizumab and Bevacizumab as neoadjuvant treatment in Hepatocellular Carcinoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Cancer type
Hepatocellular Carcinoma
Disease stage
Grade: Grade 3Grade 4
Initially resectable with high-risk recurrence factors. High-risk features for resected patients include tumor size >5 cm, tumor number >3, vascular invasion (microvascular invasion or macrovascular invasion - Vp1/Vp2 - of the portal vein) and poor tumor differentiation (defined as Grade 3 or 4).
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: locoregional or systemic treatment
No prior locoregional or systemic treatment for HCC
Cannot have received: investigational therapy
Treatment with investigational therapy within 28 days prior to initiation of study treatment
Lab requirements
Liver function
child-pugh a
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07239245 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages